N-(6-chloro-7-fluoro-5-phenyl-1H-indazol-3-yl)butyramide

ID: ALA1086427

PubChem CID: 46881853

Max Phase: Preclinical

Molecular Formula: C17H15ClFN3O

Molecular Weight: 331.78

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  CCCC(=O)Nc1n[nH]c2c(F)c(Cl)c(-c3ccccc3)cc12

Standard InChI:  InChI=1S/C17H15ClFN3O/c1-2-6-13(23)20-17-12-9-11(10-7-4-3-5-8-10)14(18)15(19)16(12)21-22-17/h3-5,7-9H,2,6H2,1H3,(H2,20,21,22,23)

Standard InChI Key:  PREQLWGLUIHGJV-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 23 25  0  0  0  0  0  0  0  0999 V2000
   15.6902  -10.1958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.6891  -11.0232    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4039  -11.4360    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4021   -9.7830    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.1175  -10.1922    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.1177  -11.0232    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.9082  -11.2798    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.3965  -10.6073    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.9078   -9.9352    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.1624   -9.1492    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.8804   -8.7428    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.5913   -9.1614    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.8874   -7.9178    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   20.3093   -8.7550    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.0202   -9.1735    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.9762  -11.4354    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   14.9778   -9.7836    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.9789   -8.9575    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.2652   -8.5453    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.5498   -8.9580    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.5527   -9.7873    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.2670  -10.1958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4041  -12.2610    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
 10 11  1  0
 11 12  1  0
  2  3  1  0
 11 13  2  0
  3  6  2  0
 12 14  1  0
  1  2  2  0
 14 15  1  0
  5  4  2  0
  2 16  1  0
  6  7  1  0
  7  8  1  0
 17 18  2  0
  8  9  2  0
 18 19  1  0
  9  5  1  0
 19 20  2  0
  4  1  1  0
 20 21  1  0
  9 10  1  0
 21 22  2  0
 22 17  1  0
  1 17  1  0
  5  6  1  0
  3 23  1  0
M  END

Associated Targets(Human)

GSK3B Tclin Glycogen synthase kinase-3 beta (11785 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CDK1 Tchem Cyclin-dependent kinase 1 (3927 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CDK2 Tchem Cyclin-dependent kinase 2 (9050 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mapt Microtubule-associated protein tau (6 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 331.78Molecular Weight (Monoisotopic): 331.0888AlogP: 4.76#Rotatable Bonds: 4
Polar Surface Area: 57.78Molecular Species: NEUTRALHBA: 2HBD: 2
#RO5 Violations: HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 8.95CX Basic pKa: 1.06CX LogP: 4.67CX LogD: 4.66
Aromatic Rings: 3Heavy Atoms: 23QED Weighted: 0.72Np Likeness Score: -1.05

References

1. Lesuisse D, Dutruc-Rosset G, Tiraboschi G, Dreyer MK, Maignan S, Chevalier A, Halley F, Bertrand P, Burgevin MC, Quarteronet D, Rooney T..  (2010)  Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2.,  20  (6): [PMID:20167481] [10.1016/j.bmcl.2010.01.114]

Source